Navigation Links
Medinox Announces Clinical Results of Naproxen Prodrug
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- Medinox, Inc. (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. (Waltham, MA) announced the results of a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented NCE prodrug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to significantly reduce the GI safety risks, including the formation of ulcers, associated with naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

In this study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced statistically significantly fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the blood stream, it is converted rapidly and quantitatively to naproxen. It is being developed to provide therapeutic levels of naproxen while avoiding high local concentrations of naproxen in the GI tract, thereby reducing the local GI toxicity associated with conventional naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and multiple-dose clinical studies. In all cases, there were no serious adverse events and LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritics, including both rheumatoid arthritis (RA) and osteoarthritis (OA). The use of NSAIDs is associated with serious side effects, the most frequent being an increased rate of gastric and duodenal ulcers. In the United States alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion a year. Serious NSAID-induced GI complications such as hemorrhage and perforation are directly responsible for about 20,000 deaths per year in the United States.

About Medinox, Inc.

Medinox, based in Carlsbad, CA, is a privately held biotechnology company, focused on developing novel therapeutic drugs for treating inflammation and septic shock. For more information about Medinox and its products, visit the company's website at www.medinox.com., or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc. at cslai@medinox.com.

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include SV Life Sciences, Burrill and Company, Novo Ventures A/S and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltherapeutics.com.


'/>"/>
SOURCE Medinox, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Rebates, Inc. Announces the Launch of My HSA Rewards
2. Pro-cell Announces a Knock at the Door of Emerging Markets
3. March of Dimes Announces Nursing Scholarship Recipients
4. The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout
5. AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR
6. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
7. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
8. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
9. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
10. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
11. Medstrat Announces Integration of Echoes With MacPractices EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in wound care advancements to physician colleagues, skilled nursing facility medical directors and ... the Treacherous Waters of Wound Care." , "At many of these conferences we ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: